NCT06348576View on ClinicalTrials.gov

Phase III Study to Evaluate the Efficacy and Safety of AD-209

PHASE3RecruitingINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

May 20, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions
Hypertension,Essential
Interventions
DRUG

AD-209

PO, Once daily(QD), 8weeks

DRUG

AD-2091

PO, Once daily(QD), 8weeks

DRUG

AD-209 Placebo

PO, Once daily(QD), 8weeks

DRUG

AD-2091 Placebo

PO, Once daily(QD), 8weeks

Trial Locations (1)

Unknown

RECRUITING

Korea University Guro Hospital, Seoul

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY